RemeGen Co. Ltd. Class A
688331
Peringkat dalam Saham
#2420
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Harga Saham
$14.49
Kapitalisasi Pasar
$8.11B
Perubahan (1 hari)
2.99%
Perubahan (1 tahun)
9.18%
Negara
CN
Perdagangan RemeGen Co. Ltd. Class A (688331)
Kategori
Healthcare
Jumlah saham beredar untuk RemeGen Co. Ltd. Class A (688331)
Jumlah saham beredar per June 2026: 560.16M
Menurut laporan keuangan terbaru dan harga saham RemeGen Co. Ltd. Class A, jumlah saham beredar saat ini adalah 560.16M. Pada akhir December 2023, perusahaan memiliki 539.72M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk RemeGen Co. Ltd. Class A (688331) dari 2018 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 560.16M | 4.24% |
| 2024 | 537.39M | -0.43% |
| 2023 | 539.72M | 1.81% |
| 2022 | 530.12M | 8.76% |
| 2021 | 487.44M | 19.43% |
| 2020 | 408.15M | -14.68% |
| 2019 | 478.36M | 0.00% |
| 2018 | 478.36M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | -54.67% |
US
|
|
| 396.00M | -29.31% |
US
|
|
| 478.91M | -14.51% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -88.90% |
NL
|
